The vaccine contract manufacturing market is segmented on the basis of vaccine type, workflow, and application. Attenuated and inactivated vaccines accounted for 56% share of the total market in 2017. However, DNA vaccines are growing at the lucrative pace owing to technological advances in genetic engineering techniques coupled with ongoing research activities for this vaccines type. Furthermore, contract services for downstream processing of vaccine production dominated its counterpart segment. This can be attributed to the growing requirement of robust technologies as well as operational infrastructure for final product recovery. CMOs/CROs produce vaccines for both animals and humans. Contract services for human-use vaccine production held a major share, owing to increasing innovation in vaccines and growing demand for the same to combat tropical diseases.

Chapter 1 Executive Summary 

Chapter 2 Research Methodology 

Chapter 3 Market Variables, Trends& Scope

Chapter 4 Market Categorization: Vaccine Type Estimates &

Trend Analysis

Chapter 5 Market Categorization: Workflow Estimates &

Trend Analysis

Chapter 6 Market Categorization: Application Estimates &

Trend Analysis

Chapter 7 Market Categorization: Regional Estimates &

Trend Analysis, by Vaccine Type, Workflow, and

Application

Chapter 8 Competitive Landscape